- Investing Ideas
- /
- Australian Biotech Stocks
Australian Biotech Stocks
Results
39
39 companies
CSL
Market Cap: AU$124.8b
Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$253.30
7D
0.2%
1Y
-9.6%
Telix Pharmaceuticals
Market Cap: AU$8.6b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.
TLX
AU$23.63
7D
-14.7%
1Y
89.6%
Mesoblast
Market Cap: AU$2.4b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$1.77
7D
-12.6%
1Y
104.0%
Neuren Pharmaceuticals
Market Cap: AU$1.3b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$9.86
7D
-19.6%
1Y
-52.5%
Botanix Pharmaceuticals
Market Cap: AU$775.9m
Engages in the research and development of dermatology and antimicrobial products in Australia and the United States.
BOT
AU$0.40
7D
-13.0%
1Y
70.2%
PYC Therapeutics
Market Cap: AU$633.6m
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$1.09
7D
-12.8%
1Y
17.2%
Mayne Pharma Group
Market Cap: AU$587.4m
A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
MYX
AU$7.21
7D
-0.4%
1Y
-0.3%
Clinuvel Pharmaceuticals
Market Cap: AU$546.9m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$10.54
7D
-9.8%
1Y
-33.8%
Immutep
Market Cap: AU$378.5m
A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.26
7D
-12.1%
1Y
-37.0%
Imugene
Market Cap: AU$209.0m
A clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.
IMU
AU$0.026
7D
-21.2%
1Y
-75.2%
Aroa Biosurgery
Market Cap: AU$151.8m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.41
7D
-5.7%
1Y
-27.2%
Paradigm Biopharmaceuticals
Market Cap: AU$128.5m
Engages in the research and development of therapeutic products for human use in Australia.
PAR
AU$0.30
7D
-17.8%
1Y
-9.1%
Trajan Group Holdings
Market Cap: AU$118.8m
Develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.78
7D
-9.9%
1Y
-35.4%
Genetic Signatures
Market Cap: AU$107.9m
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.
GSS
AU$0.49
7D
-1.0%
1Y
-29.3%
Vita Life Sciences
Market Cap: AU$102.9m
A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.
VLS
AU$1.85
7D
-3.1%
1Y
-19.6%
Arovella Therapeutics
Market Cap: AU$83.0m
A biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally.
ALA
AU$0.077
7D
-9.4%
1Y
-33.0%
LTR Pharma
Market Cap: AU$70.6m
A biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.
LTP
AU$0.36
7D
-29.1%
1Y
21.7%
EZZ Life Science Holdings
Market Cap: AU$69.8m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally.
EZZ
AU$1.46
7D
-5.8%
1Y
114.7%
Medical Developments International
Market Cap: AU$57.5m
Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.
MVP
AU$0.52
7D
-3.7%
1Y
-14.0%
Radiopharm Theranostics
Market Cap: AU$56.0m
Engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.
RAD
AU$0.023
7D
-17.9%
1Y
-54.9%
IDT Australia
Market Cap: AU$40.8m
Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the Unites States.
IDT
AU$0.092
7D
-12.4%
1Y
19.5%
Cynata Therapeutics
Market Cap: AU$40.7m
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
CYP
AU$0.17
7D
-13.2%
1Y
-15.4%
Cryosite
Market Cap: AU$38.8m
Provides outsourced clinical trials logistic services in Australia.
CTE
AU$0.80
7D
0.6%
1Y
14.3%
Little Green Pharma
Market Cap: AU$36.3m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.12
7D
-4.0%
1Y
-14.3%
Amplia Therapeutics
Market Cap: AU$25.2m
A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
ATX
AU$0.06
7D
-16.7%
1Y
-23.1%
Noxopharm
Market Cap: AU$23.1m
A biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia.
NOX
AU$0.07
7D
-17.6%
1Y
7.7%
ECS Botanics Holdings
Market Cap: AU$16.8m
Engages in the cultivation, manufacture, and sale of medicinal cannabis products in Northwest Victoria.
ECS
AU$0.013
7D
-3.8%
1Y
-45.7%
Immuron
Market Cap: AU$15.2m
A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.
IMC
AU$0.063
7D
-8.7%
1Y
-40.0%
Tissue Repair
Market Cap: AU$14.5m
A clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia.
TRP
AU$0.24
7D
-5.8%
1Y
14.0%
Emyria
Market Cap: AU$13.4m
Engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia.
EMD
AU$0.027
7D
-15.6%
1Y
-56.5%
Althea Group Holdings
Market Cap: AU$10.7m
Manufactures, distributes, and sells cannabis-based medicines and recreational cannabis products in Australia, the United Kingdom, Canada, Germany, and Ireland.
AGH
AU$0.022
7D
0%
1Y
-35.3%
Acrux
Market Cap: AU$9.3m
Engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.
ACR
AU$0.022
7D
-4.3%
1Y
-68.1%
Epsilon Healthcare
Market Cap: AU$7.2m
Epsilon Healthcare Limited operates as a healthcare and pharmaceuticals company primarily in Australia and Canada.
EPN
AU$0.024
7D
0%
1Y
20.0%
Chimeric Therapeutics
Market Cap: AU$6.5m
A clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia.
CHM
AU$0.004
7D
-20.0%
1Y
-86.7%
NeuroScientific Biopharmaceuticals
Market Cap: AU$5.6m
Engages in the research and development of novel peptide-based pharmaceutical products.
NSB
AU$0.036
7D
-2.7%
1Y
-44.6%
Genetic Technologies
Market Cap: AU$5.7m
A molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
GTG
AU$0.039
7D
0%
1Y
-68.8%